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Major determinants of hyperhomocysteinemia in peritoneal dialysis
patients. The mechanisms leading to elevated total homocysteine concen-
trations in peritoneal dialysis patients are only partially understood. We
show that a common polymorphism in the 5,10-methylenetetrahydrofolate
reductase (MTHFR) gene (C677T transition) results in increased total
homocysteine levels in peritoneal dialysis patients compared to age- and
sex-matched healthy individuals. The allelic frequency of the C677T
transition in the MTHFR gene in peritoneal dialysis patients (0.29) was
comparable to the frequency in healthy individuals (0.34). Separate
comparison of the total homocysteine plasma levels between non-carriers
of the MTHFR polymorphism (C/C), heterozygous (C/T) and homozy-
gous (T/T) subjects was performed by analysis of covariance in the patient
and the control group. In the patient group the mean total homocysteine
level was 61.7 6 40.1 mmol/liter in individuals with the (T/T) genotype,
which was significantly higher than the total homocysteine concentration
of 23.1 6 15.8 mmol/liter in (C/T) patients and 22.2 6 11.1 mmol/liter for
non-carriers (P 5 0.0001). Vitamin B12 (P 5 0.0001), folate (P 5 0.0005),
serum creatinine (P 5 0.016), albumin (P 5 0.0157) and dialysis center
(P 5 0.0173) significantly influenced total homocysteine plasma levels in
peritoneal dialysis patients, whereas this was not the case for age, gender,
weekly Kt/V, weekly creatinine clearance, residual renal function, dura-
tion of dialysis, mode of peritoneal dialysis and vitamin intake. Folate
levels in peritoneal dialysis patients were significantly affected by the
MTHFR genotype (P 5 0.016). Elevated total homocysteine levels in
diabetic patients with cardiovascular disease were associated with in-
creased cardiovascular morbidity. In summary, the present study provides
evidence that homozygosity for the C677T transition in the MTHFR gene,
low vitamin B12 and low folate levels result in elevated total homocysteine
levels in peritoneal dialysis patients.
Hyperhomocysteinemia is frequently observed in patients with
chronic renal failure and represents an independent cardiovascu-
lar risk factor in these patients [1–5]. Recently, a common C to T
mutation at nucleotide position 677 of the 5,10-methylenetetra-
hydrofolate reductase (MTHFR) gene was identified, which may
cause elevated total homocysteine plasma levels on the basis of a
decreased MTHFR activity and result in lower folate levels in
(T/T) homozygous subjects [6–9]. In chronic hemodialysis pa-
tients the allelic frequency of 0.35 of the T allele has been shown
to be in line with the frequency of 0.34 in individuals without renal
failure [10]. The mean total homocysteine plasma level in hemo-
dialysis patients homozygous for the (T/T) allele was 36.4 mmol/
liter, which was 43% higher compared to total homocysteine
concentrations of 25.4 mmol/liter in patients without mutation and
was 3.8 times higher than the mean value of 9.6 mmol/liter in
healthy non-carriers [10]. Thus far, the mechanisms underlying
hyperhomocysteinemia in peritoneal dialysis patients have only
been investigated either in small patient populations [3, 11–15] or
in patient populations differing in dialysis procedure or ethnic
origin [2, 4, 16].
We studied the influence of the (C677T) polymorphism in the
MTHFR gene on total homocysteine levels as well as plasma
folate concentrations in 154 patients maintained on peritoneal
dialysis treatment at five peritoneal dialysis units in Austria.
Additionally, we analyzed the impact of residual renal function,
Kt/V, weekly creatinine clearance, age, gender, folate levels,
vitamin B12 concentrations, creatinine levels, serum albumin
concentrations, dialysis center, duration of dialysis, mode of
peritoneal dialysis and vitamin intake on total homocysteine
levels. Cardiovascular morbidity related to total homocysteine
plasma levels was assessed using an arbitrary atherosclerosis
score.
METHODS
Study population
One hundred fifty-four patients with end-stage renal failure
treated at five peritoneal dialysis units in Austria were investi-
gated. The age of these patients (69 females, 85 males) was 54.0 6
15.1 years (mean 6 SD). Dialysis treatment was initiated because
of end-stage renal disease due to diabetic nephropathy (N 5 47),
shrunken kidneys of unknown etiology (N 5 36), chronic glomer-
ulonephritis (N 5 27), chronic interstitial nephritis (N 5 16),
polycystic kidney disease (N 5 10), nephrosclerosis (N 5 10) and
miscellaneous nephropathies in 8 cases. In 20 of the 154 patients
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peritoneal dialysis was initiated because of secondary kidney graft
failure. Twenty-seven patients previously treated with hemodial-
ysis had been switched to peritoneal dialysis. The mean duration
of peritoneal dialysis treatment was 1.46 6 1.27 years. One
hundred twenty-one patients were maintained on continuous
ambulatory peritoneal dialysis (CAPD) and 33 were treated with
automated peritoneal dialysis (APD), including 22 patients on
continuous cyclic peritoneal dialysis (CCPD) and 11 patients on
intermittent peritoneal dialysis (IPD). Twenty-six of the patients
received low dose oral vitamin supplementation therapy routinely
(consisting of low dose folate and/or low dose vitamin B12 and/or
low dose vitamin B6). To calculate weekly Kt/V and creatinine
clearance, each patient was instructed to collect 24-hour dialysate
and urine and to bring a 10 ml sample for laboratory analyses. The
average of renal urea clearance and renal creatinine clearance was
used to calculate residual renal clearance. The total weekly
residual renal and dialysate creatinine clearance was related to
1.73 m2 of body surface area. All clearance measurements were
performed using blood, dialysate and urine samples obtained at
the same time-point.
The prevalence of cardiovascular complications was assessed
according to Robinson and colleagues [3]. Coronary artery disease
and cerebral artery disease was diagnosed if a stenosis of . 50%
was envisaged by angiography or duplex-sonography. Two arbi-
trary vascular disease scores (VDS 1 and VDS 2) were calculated,
based on whether or not the patient suffered from arterial
occlusive disease in the coronary, cerebral or peripheral vascular
system (VDS 1; 1 point for each affected vascular system; possible
score, range 0 to 3). The second score (VDS 2) was applied on the
basis of the first score including one additional point for infarc-
tion/gangrene or vascular surgery or angioplasty in the different
vascular systems (possible score, range 0 to 6). The patient
characteristics are summarized in Table 1.
Age- and sex-matched healthy subjects (N 5 154) with normal
kidney function and without clinical evidence of cardiovascular
disease were selected from 298 healthy volunteers in whom
MTHFR-alleles, total homocysteine, folate and vitamin B12 levels
were available.
Written informed consent was given by all patients according to
the Declaration of Helsinki and the Austrian Law on Gene
Technology.
Biochemical assays
Fasting citrated blood was collected, immediately placed on ice
and centrifuged within 60 minutes at 2000 g at 4°C (20 min).
Plasma aliquots were snap frozen and stored at 270°C. Citrated
blood was kept at 220° for isolation of DNA. All laboratory
investigations were performed at the Department of Laboratory
Medicine at the University of Vienna.
Total (that is, free plus protein-bound) plasma homocysteine
concentrations were determined by automated high-performance
liquid chromatography (HPLC) with reverse-phase separation
and fluorescent detection using a commercially available kit
(Immundiagnostik, Bensheim, Germany) according to the
method originally described by Araki and Sako [17]. Hyperhomo-
cysteinemia was defined as total homocysteine levels above 15
mmol/liter.
Plasma folate (5-methyltetrahydrofolate) and vitamin B12 levels
were measured with a radioassay which allowed simultaneous
determination of both vitamin concentrations in a single reaction
tube (SimulTRAC-SNB, Becton Dickinson, Ontario, Canada).
Folate deficiency was considered present at a plasma concentra-
tion of less than 3.4 nmol/liter. Vitamin B12 deficiency was defined
as a concentration of less than 118 pmol/liter, respectively.
Polymerase chain reaction analysis of MTHFR gene
Identification of the 677 C to T transition in the MTHFR gene
was performed as previously described [6]. In brief, 500 ml of
citrated blood was frozen twice (270°C). Cellular DNA was
obtained by thawing and boiling for 10 minutes, followed by
centrifugation at 12,000 g (10 min). The supernatants were
collected and 5 ml of a 1:10 dilution were used in a 50 ml
polymerase chain reaction (PCR) reaction containing 10 mM
Tris-HCl (pH 8.8), 50 mM KCl, 0.1% Triton X-100, 1.25 mM
MgCl2, 0.2 mM of each nucleoside triphosphate, 30 pmol of each
primer and 1.25 units of AmpliTaq DNA Polymerase (Perkin
Elmer Cetus, Norwalk, CT, USA). PCR was performed using the
primers described by Frosst and colleagues: 59-TGAAG-
GAGAAGGTGTCTGCGGGA-39 and 59-AGGACGGTGCG-
GTGAGAGTG-39 [6]. Thermocycling conditions consisted of 40
cycles of denaturation at 95°C for one minute, annealing at 60°C
for one minute and extension at 72°C for one minute, preceded by
an initial denaturation step at 95°C for three minutes and followed
by a terminal extension of five minutes at 72°C. Two microliters of
the 198-bp PCR product were subjected to HinfI digestion (0.5
Units enzyme in a 20 ml digest). The presence of a mutation
creates a HinfI recognition sequence that leads to digestion of the
198 bp PCR product into fragments of 175 bp and 23 bp,
respectively. Heterozygous subjects show three fragments (198 bp,
175 bp and 23 bp), whereas a homozygous C to T transition results
in the production of two fragments of 175 bp and 23 bp. HinfI
digests of PCR amplification products were analyzed by electro-
phoresis through 6% polyacrylamide gels (Novex, San Diego, CA,
USA) followed by ethidium bromide staining.
Statistical methods
Comparison of the frequency of the different MTHFR alleles in
peritoneal dialysis patients and the control group was performed
by chi square test. Since plasma total homocysteine and folate
measures were positively skewed, natural logarithmic transforma-
tion was used to normalize the distribution (natural logarithm of
total homocysteine/folate concentrations, ln-total homocysteine/
ln-folate). Descriptive statistics included mean values 6 SD,
geometric means, medians, full ranges and 10th to 90th percentile
ranges for total homocysteine plasma levels, vitamin B12 and
folate levels.
Separate comparisons of the total homocysteine plasma levels
Table 1. Characteristics of 154 peritoneal dialysis patients
Sex female/male 69/85
Age years 54.0 6 15.1
Mean duration of peritoneal dialysis years 1.46 6 1.27
CAPD/APD patients 121/33
Mean weekly Kt/V 2.2 6 0.5
Mean total creatinine clearance liter/week 77.0 6 28.0
Residual renal clearance ml/min 3.28 6 3.12
Patients with vascular disease % 67 (43.5)
Diabetic patients % 47 (30.5)
Data are given as means 6 SD. Abbreviations are: CAPD continuous
ambulatory peritoneal dialysis; APD automated peritoneal dialysis.
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between (C/C), (C/T) or (T/T) subjects were performed by
analysis of covariance. The covariables were folate, vitamin B12,
age, gender, albumin, serum creatinine, weekly Kt/V, weekly
creatinine clearance, residual renal function, dialysis center, mode
of peritoneal dialysis (CAPD or APD) and vitamin intake in
peritoneal dialysis patients. Individual comparisons between the
groups were conducted by post hoc analysis (Scheffe’s test).
For both the patient and the control group (factor: group) an
analysis of covariance with the factors MTHFR [dummy variables:
(C/C) versus (T/T) and (C/T) versus (T/T)] and group, the
covariables age, gender, folate and B12 level, which were available
for both groups (patients and controls), and the calculations for
interaction terms group 3 MTHFR, group 3 age, group 3
gender, group 3 plasma folate levels and group 3 B12 levels on
the total homocysteine plasma levels were performed.
A similar model was applied for the analysis of influence of
MTHFR (dummy variables, see above) and group as factors, and
the covariables age and gender and the interaction terms group 3
MTHFR, group 3 age, group 3 gender on plasma folate levels.
Unpaired comparisons of patient characteristics in subjects with
and without cardiovascular disease and comparison of VDS 1 and
VDS 2 in patients with total homocysteine levels above versus
below the sample median or above versus below the cut off value
of the normal range (# 15.0 mmol/liter) were performed by
Student’s t-test (two tailed). All calculations were performed by
the statistical software package SAS (SAS Institute Inc., Cary,
NC, USA).
RESULTS
MTHFR gene polymorphism
In peritoneal dialysis patients the allelic frequency of the 677 C
to T transition in the MTHFR gene was 0.29 and in age- and
sex-matched healthy controls it was 0.34. Twelve of 154 patients
(7.8%) showed a homozygous C677T mutation (T/T), 65 patients
(42.2%) were heterozygous (C/T) and 77 patients (50.0%) did not
carry this mutation (C/C). In the control group 21 of 154 healthy
individuals (13.6%) were homozygous for the T allele, 64 (41.6%)
were (C/T) and in 69 control subjects (44.8%) the mutation was
not present. Comparison of the frequencies of the different
MTHFR alleles in healthy subjects and peritoneal dialysis patients
revealed no significant difference. The allelic frequency in the
group of diabetic patients (0.29; N 5 47; Table 2) was similar to
the allelic frequency in non-diabetic patients.
Total homocysteine plasma levels
Total homocysteine plasma levels were transformed to natural
logarithmic data to normalize the distribution. The mean total
homocysteine level in peritoneal dialysis patients was 25.6 6 19.8
mmol/liter versus 9.7 6 3.3 mmol/liter in control subjects.
Forty-six of 154 peritoneal dialysis patients (29.9%) had total
homocysteine levels # 15.0 mmol/liter, in contrast to 145 of 154
healthy subjects (94.2%). Of these 46 patients [23 patients were
(C/T) and 22 patients (C/C), respectively], only one was homozy-
gous for the MTHFR gene variation, whereas in the control group
19 of 145 subjects with total homocysteine levels # 15.0 mmol/liter
were identified as homozygotes for the MTHFR mutation. The
geometric mean total homocysteine levels in (T/T) patients were
more than two times higher than total homocysteine levels of
(C/T) patients and patients without the mutation (Table 3).
There was a significant influence of the MTHFR gene-polymor-
phism (P 5 0.0001), vitamin B12 (P 5 0.0001), folate (P 5 0.0005),
creatinine (P 5 0.016), serum albumin levels (P 5 0.0157) and
dialysis center (P 5 0.0173) on ln-total homocysteine plasma
levels in peritoneal dialysis patients. The mean total homocysteine
level was 61.7 6 40.1 mmol/liter in (T/T) peritoneal dialysis
patients [P , 0.05 vs. (C/T) and (C/C) patients] and 10.4 6 5.7
mmol/liter in (T/T) controls. In (C/T) patients the mean total
homocysteine concentration was 23.1 6 15.8 mmol/liter versus
9.8 6 2.9 mmol/liter in (C/T) controls. In (C/C) peritoneal dialysis
patients the mean total homocysteine level was 22.2 6 11.1
mmol/liter versus 9.4 6 2.5 mmol/liter in (C/C) controls (Fig. 1).
The (T/T) allele resulted in an estimated increase in total
homocysteine levels of 127% (more than doubling) compared to
the (C/T) and as much as 150% compared to the (C/C) patients.
An increase of the vitamin B12 level of 100 pmol/liter resulted in
an estimated decrease of total homocysteine levels of 8.9%, and
an increase of folate levels of 10 nmol/liter resulted in a decrease
of 4%. In contrast, an increase of serum albumin level of 1 g/liter
resulted in an estimated increase of 2% and an increase of
creatinine of 1 mg/dl resulted in an estimated increase of total
homocysteine levels of 7%. The significant center effect in our
analysis was due to relative many (T/T) patients with high total
homocysteine plasma levels in one small center. The other
covariables (weekly Kt/V, residual renal clearance, weekly creat-
inine clearance, age, gender, duration of dialysis, and vitamin
intake) showed no significant influence on total homocysteine
levels.
For the overall analysis of ln-total homocysteine levels of
patients and controls, there was a significant influence of the
factor group (P 5 0.0001), of the covariables age (P 5 0.0006) and
gender (P 5 0.0003), and significant interaction terms group 3
MTHFR [for (C/C) versus (T/T), P 5 0.0001, for (C/T) versus
(T/T), P 5 0.0001], group 3 age (P 5 0.0002), and group 3 B12
level (P 5 0.0002). The total homocysteine levels were more than
twofold higher in the patient group than in the control group.
Furthermore, total homocysteine levels significantly varied among
the MTHFR groups of the patient group and the control group.
The most striking finding was that patients homozygous for the T
allele had particularly high total homocysteine values (Table 3).
The total homocysteine levels in the control group were increasing
in older control people, whereas in the patient group the total
homocysteine levels were nearly constant with advancing age. In
the control group there was no influence of vitamin B12 levels on
Table 2. Genotypes and allelic frequency of the C677T MTHFR
polymorphism in peritoneal dialysis patients and age- and sex-matched
control subjects
MTHFR
(C677T)
polymorphism
Peritoneal dialysis
patients
(N 5 154)
Control
subjects
(N 5 154)
Diabetic
patients
(N 5 47)
(T/T) 12 (7.8%) 21 (13.6%) 3 (6.4%)
(C/T) 65 (42.2%) 64 (41.6%) 21 (44.7%)
(C/C) 77 (50.0%) 69 (44.8%) 23 (48.9%)
Allelic frequency 0.29 0.34 0.29
There were no significant differences in the frequencies of different
MTHFR genotypes or allelic frequencies between peritoneal dialysis
patients, the subgroup of diabetic patients and control subjects.
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total homocysteine levels, while in the patient group a negative
correlation was observed. Folate levels had no influence on total
homocysteine concentrations in this analysis including both pa-
tients and controls.
Vitamin concentrations
The mean folate concentration was 22.9 6 36.6 nmol/liter
(normal range, 3.4 to 38 nmol/liter) in peritoneal dialysis patients
versus 16.1 6 8.2 nmol/liter in control subjects. For the analysis of
folate levels the factor MTHFR [only the dummy (C/C) versus
(T/T) was significant, P 5 0.016] and group (P 5 0.0146) were
significant. This reflects that the behavior of the folate level is
slightly different between control and patient group and between
(C/C) and (T/T) mutated MTHFR alleles. The mean vitamin B12
concentration was 336.1 6 242.1 pmol/liter in the patient group
(normal range, 118 to 720 pmol/liter) versus 263.9 6 184.7
pmol/liter in healthy subjects. Not one of the peritoneal dialysis
patients or the healthy controls had a folate deficiency. Deficiency
of vitamin B12 was identified in 9 of 154 patients (5.8%) and in 8
of 154 control subjects (5.2%). The mean vitamin B12 level was
96.1 6 17.7 pmol/liter in B12 deficient patients and 99.5 6 12.0
pmol/liter in B12 deficient control subjects. The mean total
homocysteine level was 35.0 6 18.9 mmol/liter in this patient
group and 11.6 6 2.4 mmol/liter in the control individuals,
including 5 patients and 3 controls with a (C/T) and 3 patients and
2 controls with a (T/T) genotype. Folate and vitamin B12 levels
according to MTHFR subgroups are indicated in Table 3.
Cardiovascular disease and relation to total homocysteine
levels
Sixty-seven of 154 patients had evidence of vascular disease
(43.5%). In patients with cardiovascular disorders, the geometric
mean total homocysteine level was 18.5 mmol/liter versus 22.8
mmol/liter in those without vascular disease (NS). The only
significant differences between these two patient groups were the
patients’ gender and age, creatinine and serum albumin levels and
the number of diabetic patients (Table 4). Vascular disease scores
were analyzed in all patients with cardiovascular disease and in
vascular disease patients with and without diabetes mellitus. The
mean VDS 1 and mean VDS 2 in patients with cardiovascular
disease and in patients with and without diabetes mellitus with
respect to total homocysteine concentrations are summarized in
Table 5. Diabetic patients with total homocysteine levels above
the sample median had a higher mean VDS 1 and VDS 2
compared to patients with total homocysteine levels below the
sample median (Table 5).
DISCUSSION
The present study demonstrates that peritoneal dialysis patients
who are homozygous for the C677T polymorphism in the
Table 3. MTHFR (C677T) alleles, total homocysteine (mmol/liter), folate (nmol/liter) and vitamin B12 (pmol/liter) plasma levels in 154 peritoneal
dialysis patients and 154 age- and sex-matched controls (controls in parenthesis)
MTHFR alleles Number Mean 6 SD
Geometric
mean Median Range
10th
percentile
90th
percentile
Total
homocysteine
plasma levels
(T/T) 12 (21) 61.7 6 40.1 (10.4 6 5.7) 48.8 (9.4) 58.8 (9.0) 127.2 (26.0) 16.2 (6.2) 113.2 (14.8)
(C/T) 65 (64) 23.1 6 15.8 (9.8 6 2.9) 19.3 (9.4) 19.4 (9.6) 73.7 (14.5) 9.8 (6.8) 38.2 (13.8)
(C/C) 77 (69) 22.2 6 11.1 (9.4 6 2.5) 19.5 (9.0) 20.9 (8.9) 49.6 (12.7) 8.4 (6.1) 37.1 (12.9)
Total 154 (154) 25.6 6 19.8 (9.7 6 3.3) 20.8 (9.2) 20.7 (9.2) 135.1 (27.1) 9.3 (6.5) 46.5 (13.7)
Folate plasma
levels
(T/T) 12 (21) 47.3 6 114.2 (12.8 6 4.8) 16.6 (12.0) 12.0 (12.0) 403.3 (19.3) 6.9 (7.8) 33.1 (19.3)
(C/T) 65 (64) 23.5 6 26.6 (15.1 6 5.8) 17.8 (14.1) 16.4 (13.8) 180.2 (25.1) 8.4 (8.3) 35.5 (23.5)
(C/C) 77 (69) 18.7 6 9.9 (18.1 6 10.2) 16.5 (16.3) 14.8 (15.6) 39.2 (70.9) 9.8 (9.9) 35.0 (31.7)
Total 154 (154) 22.9 6 36.6 (16.1 6 8.2) 17.1 (14.7) 15.5 (14.5) 403.3 (72.0) 8.7 (8.9) 35.0 (23.9)
Vitamin B12
plasma levels
(T/T) 12 (21) 250.7 6 194.3 (277.9 6 257.2) 202.9 (225.5) 188.4 (204.2) 671.0 (1238.6) 91.4 (130.6) 460.0 (373.9)
(C/T) 65 (64) 334.5 6 254.7 (266.8 6 140.9) 270.6 (241.4) 242.2 (232.3) 1421.6 (861.0) 125.4 (137.8) 656.0 (396.0)
(C/C) 77 (69) 350.7 6 237.8 (257.1 6 196.9) 297.7 (226.0) 278.0 (225.0) 1345.5 (1586.2) 159.0 (132.1) 623.3 (381.3)
Total 154 (154) 336.1 6 242.1 (263.9 6 184.7) 277.5 (232.2) 256.9 (227.8) 1421.6 (1586.2) 141.0 (131.8) 628.1 (384.5)
Fig. 1. Plasma total homocysteine levels (mean 6 SD) in 154 peritoneal
dialysis patients and 154 age- and sex-matched healthy individuals with the
different (C677T) MTHFR alleles. Symbols are: (o) peritoneal dialysis
patients; (M) healthy individuals. *P , 0.05 for comparison of (T/T) versus
(C/T) and (C/C) peritoneal dialysis patients.
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MTHFR gene have significantly higher total homocysteine plasma
levels (61.7 6 40.1 mmol/liter) than heterozygous patients (23.1 6
15.8 mmol/liter) or non-carriers (22.2 6 11.1 mmol/liter). Vitamin
B12, folate, creatinine, albumin concentrations and dialysis center,
but not age, gender, weekly Kt/V, weekly creatinine clearance,
residual renal function, duration and mode of peritoneal dialysis
and the vitamin intake had a significant influence on plasma total
homocysteine concentrations. The MTHFR polymorphism also
significantly influenced plasma folate levels of peritoneal dialysis
patients and healthy subjects. In diabetic patients with vascular
disease the vascular disease morbidity was more pronounced if
total homocysteine plasma levels above the sample median were
present. The allelic frequency of the (C677T) transition in the
MTHFR gene was not different between healthy subjects, all
peritoneal dialysis patients and the subgroup of diabetic patients.
Elevated homocysteine levels were initially suspected in end-
stage renal disease patients in 1972 by Robins and colleagues [18]
and were later confirmed by others [19–22]. Subsequently, hyper-
homocysteinemia has been shown to be associated with an
increased frequency of atherosclerotic vascular disease and was
established as an independent risk factor for cardiovascular
complications in chronic renal failure patients [1–5, 23].
In the first study conducted in a small population of CAPD
patients, Hultberg, Andersson and Sterner [11] compared total
homocysteine levels in three different patient groups receiving
folate and vitamin B6 substitution therapy. The median total
homocysteine plasma level was 24.0 mmol/liter in 17 CAPD
patients, 27.9 mmol/liter in 29 hemodialysis patients, and 23.5
mmol/liter in 30 chronic renal failure patients. In this report, the
authors also studied the diurnal variations of total homocysteine
levels in a subset of these patients and did not find a significant
increase of total homocysteine levels following a meat-rich meal.
Also, in another recent study by Janssen and associates no
daytime variations of total homocysteine plasma concentrations in
CAPD patients have been observed [13].
It is well established that folate supplementation therapy has a
lowering effect on homocysteine concentrations [24, 25]. Total
homocysteine plasma levels decreased from 50.2 6 5.6 mmol/liter
to 16.6 6 1.9 mmol/liter during six weeks of folate therapy (5
mg/day) in 10 CAPD patients compared to a decrease of 55.7 6
10.1 mmol/liter to 24.0 6 2.0 mmol/liter in 10 hemodialysis patients
[12]. After 12 and 26 weeks following cessation of folate substi-
tution, total homocysteine levels gradually increased again but did
not reach the pretreatment values [12]. Kim and coworkers [14]
compared total homocysteine plasma levels in 12 CAPD patients,
5 hemodialysis patients and 10 healthy controls who did not
receive vitamin substitution therapy. Total homocysteine plasma
levels in these patients were 32.7 6 18.5 mmol/liter, 25.2 6 10.9
mmol/liter, and 14.0 6 4.0 mmol/liter, respectively. The authors
did not find a correlation with age, vitamin B6 levels, residual
renal function, protein catabolic rate or Kt/V. However, a signif-
icant correlation with an arbitrary atherosclerosis score was
observed.
Robinson and collaborators [3] investigated the risk of devel-
opment of cardiovascular disease in 176 end-stage renal failure
patients with hyperhomocysteinemia. They found an independent
odds ratio of 2.9 (confidence interval 1.4 to 5.8, P , 0.007) for
vascular complications in patients with a total homocysteine
concentration in the upper two quintiles (. 27.8 mmol/liter).
Hemodialysis patients (N 5 130) in this study showed higher total
homocysteine levels (29.5 6 1.7 mmol/liter) than peritoneal
dialysis patients (N 5 46; 19.5 6 1.7 mmol/liter, P , 0.01).
Ninety-five percent of patients with vascular disease and 54% of
patients without vascular disease were on hemodialysis treatment
[3].
The pathogenesis leading to elevated homocysteine concentra-
tions in renal failure patients is only partially understood. The
kidney itself is supposed to play a substantial role in homocysteine
metabolism, and hyperhomocysteinemia has been shown to
progress in parallel with the decline of renal function [5, 11,
26–29] despite the negligible urinary excretion of homocysteine
[30]. Bostom and colleagues demonstrated that the total homo-
cysteine content in renal vein blood of rats is much lower
compared to the total homocysteine concentration in the renal
artery [30]. Based on this observation it was speculated that
homocysteine might not reach the renal metabolic site in case of
a decreased glomerular filtration rate. Furthermore, uremic toxins
are supposed to contribute to hyperhomocysteinemia by inhibi-
tion of enzymes required for homocysteine metabolism. Perna
and colleagues demonstrated that hyperhomocysteinemia can
lead to intracellular accumulation of S-adenosyl-homocysteine,
resulting in an impairment of remethylation pathways in uremia
[31–33].
Besides age, gender and nutritional factors including vitamin
status and albumin concentration [3, 4], a genetic defect in the
MTHFR gene (C677T transition) was recently shown to result in
elevated total homocysteine concentrations in homozygous hemo-
dialysis patients [10]. The enzyme MTHFR represents an impor-
tant cofactor involved in the homocysteine remethylation path-
way. Decreased MTHFR activity results in inadequate production
Table 4. Main characteristics of 154 peritoneal dialysis patients with
and without cardiovascular disease
With vascular
disease
Without vascular
disease
No. of patients % 67 (43.5) 87 (56.5)
Gender female/male 23/44 46/41a
Age years 59.4 (60.6 6 12.1) 46.5 (49.0 6 15.2)a
Duration of peritoneal
dialysis treatment years
0.9 (1.5 6 1.4) 0.9 (1.4 6 1.2)
Diabetic patients % 33 (49.3) 14 (16.1)a
Allelic frequency of the
(C677T) MTHFR
transition
0.28 0.30
Total homocysteine
concentration mmol/
liter
18.5 (22.7 6 18.9) 22.8 (27.8 6 20.3)
Patients with tHcy levels
#15 mmol/liter %
24 (35.8) 22 (25.3)
Folate level nmol/liter 16.7 (22.3 6 26.1) 17.4 (23.4 6 43.1)
Vitamin B12 level pmol/
liter
278.5 (330.3 6 221.7) 276.8 (340.6 6 257.9)
Albumin concentration
g/liter
36.4 (37.0 6 6.3) 39.6 (39.9 6 4.8)a
Serum creatinine mg/dl 7.3 (7.5 6 2.0) 8.1 (8.4 6 2.0)a
Weekly Kt/V 2.1 (2.2 6 0.4) 2.2 (2.3 6 0.5)
Creatinine clearance
liter/week
71.7 (75.4 6 25.6) 73.6 (78.3 6 29.8)
Data are shown as geometric means and means 6 standard deviation in
parenthesis.
tHcy is total homocysteine.
a P , 0.05
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of 5-methyltetrahydrofolate, which is required for the remethyla-
tion of homocysteine to methionine, with the consequence of
elevated plasma total homocysteine concentrations [34, 35]. The
frequency of the different MTHFR alleles in our patients was
comparable to the frequency observed in age- and gender-
matched healthy individuals.
Recently, the influence of the MTHFR polymorphism on total
homocysteine plasma levels in subjects with normal renal function
was shown to be limited to those having suboptimal folate levels
[9]. Even though the homozygous (T/T) MTHFR polymorphism
may lead to elevated total homocysteine levels in healthy subjects,
the increase was not significant in this study.
In contrast, total homocysteine levels in (T/T) homozygous
peritoneal dialysis patients were significantly higher (more than
twofold) compared to (C/T) and (C/C) patients. This increase is
much higher compared to the levels in hemodialysis patients [43%
increase of total homocysteine levels in (T/T) versus (C/C)
patients] [10]. This striking difference in total homocysteine
concentrations of (T/T) hemodialysis and (T/T) peritoneal dialysis
patients might be associated with, at least in part, the lower, but
still normal folate and vitamin B12 levels observed in the group of
(T/T) peritoneal dialysis patients.
In several studies hemodialysis patients had higher total homo-
cysteine concentrations compared to peritoneal dialysis patients
[3, 11, 14]. These data are in line with our own observation on
hemodialysis patients showing a mean total homocysteine level of
28.7 6 11 mmol/liter [10] compared to the mean total homocys-
teine level of 25.6 6 19.8 mmol/liter for peritoneal dialysis patients
of this study. Peritoneal dialysis patients presented with lower
mean folate but higher mean vitamin B12 plasma levels compared
to the hemodialysis patients from our previous study (folate levels,
22.9 nmol/liter vs. 26.6 nmol/liter; vitamin B12 levels, 336.1
pmol/liter vs. 276.9 pmol/liter, respectively). Therefore, separate
analyses of the total homocysteine levels, of the influence of the
(C677T) MTHFR polymorphism, and of cofactors involved in
homocysteine metabolism, have to be performed in patients with
different modes of renal replacement therapy. Furthermore, a
separate investigation of cardiovascular risk factors, morbidity
and mortality in hemodialysis and peritoneal dialysis patients
appears to be mandatory for future studies.
There was a significant influence of vitamin B12, folate, creati-
nine, and albumin levels on total homocysteine plasma concen-
trations of peritoneal dialysis patients in the present study, which
is in line with previous observations in renal failure patients [3, 4].
It can be speculated that total homocysteine concentrations may
reflect the nutritional status because we observed a significant
influence of albumin concentrations in our analyses. However, the
distribution of patients with moderate hyperhomocysteinemia (30
to 100 mmol/liter) was comparable in patients with albumin levels
between 30 and 40 g/liter and between 40 and 50 g/liter with
respect to the different MTHFR alleles (Fig. 2). Low dose vitamin
supplementation in some of the patients had no influence on total
homocysteine concentrations in our study.
High dose folate therapy has been demonstrated to lower total
homocysteine plasma concentrations in end-stage renal failure
patients despite the commonly observed high folate levels of these
patients, which is probably linked to intracellular folate deficiency
[13, 16, 25]. A potential effect of low intracellular folate concen-
trations on total homocysteine plasma levels in our peritoneal
dialysis patients cannot be ruled out. Nevertheless, there was a
significant influence of folate plasma levels on total homocysteine
concentrations in our analyses. The homozygous C677T MTHFR
transition was recently shown to affect red cell folate and plasma
folate concentrations in pregnant women and red cell folate levels
in nonpregnant women [37]. Our study also demonstrates that the
MTHFR polymorphism significantly influences plasma folate
levels in peritoneal dialysis patients and healthy subjects [the
median folate concentration was lower in (TT) subjects compared
with (CT) and (CC) subjects; Table 3]. Thus, low 5-methyltetra-
hydrofolate levels in individuals with the (T/T) MTHFR allele do
not necessarily reflect a suboptimal folate intake, but may point to
decreased formation of active folate resulting from the presence
of a thermolabile MTHFR variant. This status leads to elevated
total homocysteine levels due to decreased conversion of homo-
cysteine to methionin, which might be overcome by increased
folate intake [24, 25].
It can be hypothesized that the extent of hyperhomocysteinemia
in dialysis patients might be influenced by geographical factors.
Recently, a European-wide survey on total homocysteine levels in
subjects without renal failure revealed significant variations in
total homocysteine plasma levels in different cities and countries
[36]. In this study genetic and nutritional influences on total
homocysteine levels were not considered [36]. In the present study
a center effect on total homocysteine levels was observed, which
was due to the relatively greater proportion of (T/T) patients with
high total homocysteine levels in a center with few patients. In
healthy subjects age and sex influence total homocysteine plasma
concentrations, whereas in patients with renal failure the MTHFR
polymorphism, folate and vitamin B12 concentrations are much
more important.
Table 5. Vascular disease scores of all 67 patients with vascular disease, of 33 vascular disease patients with diabetes mellitus and of 34 non-
diabetic vascular disease patients in relation to high and low total homocysteine plasma levels
tHcy plasma levels
All patients with vascular disease
(N 5 67)
Diabetic patients
(N 5 33)
Non-diabetic patients
(N 5 34)
Number VDS 1 VDS 2 Number VDS 1 VDS 2 Number VDS 1 VDS 2
#Sample median 34 1.53 2.44 17 1.47 2.35 17 1.59 2.53
.Sample median 33 1.76 3.00 16 2.06a 3.50b 17 1.47 2.53
Normal (#15 mmol/liter) 24 1.54 2.46 11 1.55 2.45 13 1.54 2.46
.Normal 43 1.70 2.86 22 1.86 3.14 21 1.52 2.57
Abbreviations are: VDS 1, vascular disease score 1; VDS 2, vascular disease score 2; tHcy, total homocysteine. The median total homocysteine level
was 18.4 mmol/liter for all patients with vascular disease, 18.4 mmol/liter for diabetic patients with vascular disease and 17.9 mmol/liter for non-diabetic
patients with vascular disease.
a P 5 0.0211 vs. VDS 1, and b P 5 0.020 vs. VDS 2 in diabetic patients with vascular disease and total homocysteine levels # sample median.
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In hemodialysis patients, plasma total homocysteine concentra-
tions can be transiently lowered by dialysis treatment [11, 18]. In
the present study, however, no significant influence of duration
and mode of peritoneal dialysis treatment, weekly Kt/V, residual
renal function and weekly creatinine clearance on total homocys-
teine levels was observed in peritoneal dialysis patients. These
findings extend the results obtained in previous studies describing
no influence of Kt/V on total homocysteine levels in a small
patient population [14].
The cardiovascular morbidity and mortality of dialysis patients
is increased manyfold compared to healthy subjects [37–39]. This
finding was suggested to be associated with elevated total homo-
cysteine plasma levels [1–4], although no separate analysis in
hemodialysis and peritoneal dialysis patients was conducted in
these studies. It was not the goal of the present study to
demonstrate that total homocysteine levels represent an indepen-
dent risk factor for cardiovascular disease. Therefore, lipid pro-
files, Lp(a), fibrinogen levels and other known cardiovascular risk
factors were not considered in our analyses. Interestingly, a high
proportion of our patients presented with total homocysteine
concentrations within the normal range and comparison of pa-
tients with and without evidence of cardiovascular disease re-
vealed no significant difference of total homocysteine levels in
either patient groups. It has to be mentioned, however, that there
were significantly more diabetic patients in the group with vascu-
lar disease. Furthermore, the mean age in patients with vascular
disease was significantly higher and the mean albumin level was
significantly lower in these patients. Interestingly, serum creati-
nine levels in patients with vascular disease were lower compared
to those without vascular disease. Nevertheless, we found a
significant increase of vascular morbidity in diabetic patients with
total homocysteine levels above the sample median. This finding
points to the multifactorial genesis of atherosclerosis in end-stage
renal failure patients.
In conclusion, the present study provides evidence that homozy-
gosity for the C677T polymorphism in the MTHFR gene as well
as low vitamin B12 and low folate levels result in aggravation of
hyperhomocysteinemia in peritoneal dialysis patients. Further-
more, the MTHFR polymorphism influences folate levels in both
the patient group and in healthy individuals. Elevated total
homocysteine levels in our diabetic peritoneal dialysis patients
with vascular disease are associated with increased cardiovascular
morbidity. Vitamin therapy in end-stage renal failure patients is
strongly encouraged, especially if further studies prove a benefi-
cial effect of folate or vitamin B12 intervention on vascular disease
morbidity and mortality in these patients.
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